Black Diamond Therapeutics, Inc.
NASDAQ:BDTXBiotechnology
-$0.04 today
- Market cap
- $82.18M
- Beta
- 3.23
- P/E (TTM)
- -2.2
- EPS (TTM)
- -$0.75
Volume 0.60M
Average 1.31M
BDTX Other Non-current Assets
Long-term assets not reported separately.
Black Diamond Therapeutics, Inc.NASDAQ: BDTX
Other Non-current Assets · Q1 FY2026 · quarter ended Mar 2026
Other non-current assets falls 97.2% from a year ago
Other non-current assets stood at $29K at the end of Q1 FY2026, down 97.2% from a year earlier and down 60.3% from the prior quarter. Over 3 fiscal years it compounded at -60.3% a year.
Context
- Other non-current assets amounted to 0.0% of total assets at the end of Q1 FY2026, down 0.6 pp from a year earlier.
- Other non-current assets increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether other non-current assets keeps falling in the next quarterly balance sheet after a -97.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Non-current Assets history
USD · from the balance sheet
- Latest · FY2025
- 73K USD
- Year-over-year change
- -93.2%
- 4-year CAGR
- -50.7%
| Period | Period end | Other Non-current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 73K | -93.2% |
| FY2024 | 2024-12-31 | 1.07M | +29.8% |
| FY2023 | 2023-12-31 | 823K | -29.5% |
| FY2022 | 2022-12-31 | 1.17M | -5.7% |
| FY2021 | 2021-12-31 | 1.24M | — |
Other Non-current Assets vs competitors
How BDTX compares with its peers on the latest reported figures
- Peers report in different currencies, so other non-current assets is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -97.2% is the 10th highest of 11, against a peer median of -5.2%.
- Other non-current assets amounts to 0.0% of total assets for BDTX, versus a peer median of 0.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $42.19B USD | +5202413.6% | +291.0% | 19.6% | |
| Mar 2026 | $4.74M USD | +157.2% | +606.6% | 4.8% | |
| Mar 2026 | $3.79M USD | -21.4% | -7.2% | 2.8% | |
| Mar 2026 | $2.14M USD | -57.6% | +11.9% | 1.4% | |
| Dec 2025 | €1.16M EUR | +11.0% | +6.3% | 0.5% | |
| Mar 2026 | $827K USD | +1350.9% | +162.9% | 0.4% | |
| Mar 2026 | $691K USD | -79.8% | +49.9% | 1.0% | |
| Mar 2026 | $183K USD | +39.7% | +17.0% | 0.2% | |
| Mar 2026 | $144K USD | -95.8% | -49.1% | 0.0% | |
| Mar 2026 | $29K USD | -97.2% | -60.3% | 0.0% | |
| Mar 2026 | $3K USD | -99.8% | -21.1% | 0.0% | |
| Peer median (excluding BDTX) | — | -5.2% | +14.5% | 0.7% | |
Competitors are the stored peer set for BDTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 65.8M | 34.32M | 56.22M | 36.44M | 20.99M |
| Short-term Investments | 143.99M | 88.49M | 75.18M | 62.14M | 107.66M |
| Net Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 4.9M | 2.63M | 2.6M | 3.79M |
| Total Current Assets | 215.7M | 127.71M | 134.03M | 101.18M | 132.44M |
| Property, Plant & Equipment (Net) | 30.74M | 27.38M | 23.71M | 20.4M | 9.67M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 829K |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 1.24M | 1.17M | 823K | 1.07M | 73K |
| Total Non-current Assets | 31.98M | 28.55M | 24.53M | 21.46M | 10.57M |
| Total Assets | 247.68M | 156.26M | 158.57M | 122.64M | 143.01M |
| Account Payables | 4.11M | 1.88M | 2.32M | 4.01M | 579K |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | 23.64M | 15.26M | 19.65M | 20.57M | 15.73M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 28.14M | 25.3M | 22.19M | 18.78M | 15.07M |
| Total Liabilities | 51.78M | 40.56M | 41.83M | 39.36M | 30.8M |
| Common Stock | 5K | 5K | 7K | 7K | 8K |
| Retained Earnings | (243.82M) | (334.99M) | (417.43M) | (487.11M) | (464.74M) |
| Accumulated OCI | (414K) | (1.82M) | (27K) | 24K | 101K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 195.9M | 115.7M | 116.74M | 83.29M | 112.21M |
| Total Debt | 28.46M | 28.14M | 25.3M | 22.19M | 18.78M |
| Net Debt | (37.34M) | (6.18M) | (30.92M) | (14.25M) | (2.21M) |
Black Diamond Therapeutics, Inc.
NASDAQ:BDTX
Intrinsic Alpha fair value
Locked
Current Price
$1.43
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.